Meeting Banner
Abstract #4336

Advanced imaging in lesion and normal-appearing white matter over 2 years in MS patients treated with alemtuzumab

Irene Vavasour 1 , Alex MacKay 1,2 , David Li 1 , Cornelia Laule 1,3 , and Anthony Traboulsee 4

1 Radiology, University of British Columbia, Vancouver, British Columbia, Canada, 2 Physics and Astronomy, University of British Columbia, Vancouver, British Columbia, Canada, 3 Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, 4 Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Alemtuzumab is a multiple sclerosis (MS) therapy designed to inhibit inflammation and prevent the accumulation of disability. To test the potential neuroprotective properties of the drug, we used advanced MRI to monitor changes in myelin water fraction, T2 and T1 within lesions and normal-appearing white matter over 2 years in MS patients treated with alemtuzumab. Data suggests that, while on treatment, remyelination appears more robust possibly due to an improved immunologic milieu 6 months post-alemtuzumab. Supporting this is a smaller T1 increase at new lesion appearance indicating less edema and inflammation for lesions formed while under the effects of alemtuzumab.

This abstract and the presentation materials are available to members only; a login is required.

Join Here